Exelixis Hopes CABOSUN Means New Dawn For Cabometyx In Frontline Kidney Cancer

Exelixis’s plan to file an sNDA, based on positive results in the Phase II CABOSUN study, could support an early approval for cabozantinib in first-line kidney cancer, spuring more change in the crowded kidney cancer market